Florida Atlantic University and spinout Cancer Health Solutions Resources are using a $184,000 commercialization-assistance grant from the state to conduct proof-of-concept human clinical trials for a drug against pre-cancerous skin lesions, company and university officials said this week.
 
The gap funding, which has been matched by CHS Resources for a total of $368,000, will also enable the company to continue developing a UV-protective skin lotion based on the same chemicals comprising the drug candidate.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.